Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Promazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 8/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | MTOR | P42345 | 5/20 | 1.00 |
| ▸ | KDM1A | O60341 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Promazine SCHEMBL9052694 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ATP53DRD2 | |
| Promazine SCHEMBL140489 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ATP53DRD2 | |
| Promazine SCHEMBL123418 | 0.98 | LMNA (1.00) | CYP2D6CYP1A2HTR1ATP53DRD2 | |
| Promazine SCHEMBL27425063 | 0.98 | CYP2D6 (0.97) | CYP2D6CYP1A2HTR1ATP53DRD2 | |
| Promazine SCHEMBL29390978 | 0.98 | LMNA (1.00) | CYP2D6CYP1A2HTR1ATP53DRD2 | |
| Promazine SCHEMBL27429489 | 0.98 | CYP2D6 (0.97) | CYP2D6CYP1A2HTR1ATP53DRD2 | |
| Promazine SCHEMBL123419 | 0.97 | CYP2D6 (0.94) | CYP2D6CYP1A2HTR1ATP53DRD2 | |
| Promazine SCHEMBL28239574 | 0.95 | CYP2D6 (0.91) | CYP2D6CYP1A2HTR1ATP53DRD2 | |
| SCHEMBL6865346 | 0.95 | CYP2D6 (0.90) | CYP2D6CYP1A2HTR1ATP53DRD2 | |
| Promazine SCHEMBL6855138 | 0.91 | CYP2D6 (0.83) | CYP2D6CYP1A2HTR1ATP53DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114755403-A | Use of indole derivatives as chemiluminescence enhancer and kit containing enhancer | 大连博格林生物科技有限公司 | 2022-07-15 | — | — | CN | claimed |
| US-11285111-B2 | Particle-producing method and particle-producing apparatus | RICOH COMPANY, LTD. (JP) | 2022-03-29 | — | — | US | claimed |
| CN-121257751-B | Multi-mode data set automatic construction system based on thinking chain and self-thinking | 南方电网绿能科技(广东)有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12587737-B2 | Production resource object manager | NBCUNIVERSAL MEDIA, LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-12478623-B2 | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| CN-120067090-A | Automatic generation method and system for water conservancy data quality inspection rules based on large language model | 广东省水利水电科学研究院 | 2025-05-30 | — | — | CN | disclosed |
| CN-119990995-A | Article information processing method, apparatus, and storage medium | 浙江莲荷科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250126356-A1 | PRODUCTION RESOURCE OBJECT MANAGER | NBCUNIVERSAL MEDIA, LLC (US) | 2025-04-17 | — | — | US | disclosed |
| CN-119621925-A | Document content recall method and system, storage medium, and program product | 中国银联股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119562811-A | Pharmaceutical composition | 莹硕生技医药股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-116744792-A | Liquid agrochemical composition | 诺力昂化学品国际有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116600643-A | Herbicide mixture, herbicide composition, method for controlling undesired vegetation and kit | 安道麦阿甘有限公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-4196122-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | Surge Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | disclosed |
| EP-4090969-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2022-11-23 | — | — | EP | disclosed |
| US-20220362241-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2022-11-17 | — | — | US | disclosed |
| CN-114755403-A | Use of indole derivatives as chemiluminescence enhancer and kit containing enhancer | 大连博格林生物科技有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114755403-A | Use of indole derivatives as chemiluminescence enhancer and kit containing enhancer | 大连博格林生物科技有限公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12587737-B2 | Production resource object manager | NOXO1, TEX264, RXFP2 | DRD2 3266/4885DRD3 3599/4885DRD4 3921/4885 |
| US-20220362241-A1 | NOVEL METHODS | HTR2A, HTR2C, HTR2B | DRD2 14/4885DRD3 98/4885DRD4 81/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | DRD2 4318/4885DRD3 4400/4885DRD4 4407/4885 |
| US-12478623-B2 | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor | HTR2A, HTR2C, HTR5A | DRD2 27/4885DRD3 131/4885DRD4 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.